Study Discovers a Retinal Signaling Molecule Erucamide That is Key in Preventing Vision Loss in Various Eye Diseases
Nikhil Prasad Fact checked by:Thailand Medical News Team Jul 08, 2026 1 hour, 12 minutes ago
Medical News: A team of scientists has identified a naturally occurring molecule in the eye that could open the door to an entirely new way of protecting vision in people with devastating retinal diseases. Researchers discovered that a fatty molecule known as erucamide acts as an important signaling messenger inside the retina, helping coordinate the eye's own defense system against damage. The discovery offers fresh hope for slowing the progression of conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa, which together affect millions of people worldwide.
This
Medical News report highlights research led by scientists from Scripps Research in the United States, working together with researchers from the University of California, San Diego (UC San Diego) and the Lowy Medical Research Institute.
Vision Loss Begins Long Before Blindness
Many serious eye diseases gradually destroy photoreceptors, the specialized light-sensing cells that convert light into electrical signals for the brain. Once these cells die, vision steadily declines and, in many cases, the damage cannot be reversed.
Although current treatments can slow disease progression in some patients, most therapies target individual diseases rather than strengthening the retina itself. The new study suggests that boosting one of the retina's own natural protective signals could help preserve healthy tissue regardless of the underlying cause of disease.
Scientists Uncover a Missing Protective Molecule
The research team performed advanced metabolomic and lipidomic analyses using high-resolution mass spectrometry to examine thousands of naturally occurring molecules in healthy and diseased retinas. They discovered that erucamide, a primary fatty acid amide, consistently dropped to very low levels as photoreceptors began to degenerate in several well-established mouse models of retinal disease.
According to senior author Professor Martin Friedlander of Scripps Research, this finding revealed that the retina actively fights injury rather than simply deteriorating. Co-author Professor Dale Boger, also from Scripps Research, explained that the dramatic reduction in erucamide suggested the molecule was not merely a by-product of disease but might actually control how retinal tissue responds to injury.
Protecting the Retina Through Immune Cell Communication
To determine whether replacing erucamide could slow degeneration, researchers developed a sophisticated delivery system using organosilane-modified porous silicon nanoparticles. These microscopic carriers safely transported the water-insoluble molecule throughout retinal tissue after injection into the eye.
Rather than acting directly on photoreceptors, erucamide activated specialized immune cells known as CD11b-positive myeloid cells, which play an important role in maintaining retinal health. Once activated, these immune cells released numerous protective proteins and growth factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), fibroblast growth factor-2 (FGF-2), insulin-like growth factor-1 (IGF-1), and brain-derived neurotrophic factor (BDNF).
Together, these molecules supported retinal neurons, stabilized delicate blood vessels, and strengthened communication between
nerve cells, glial cells, and the retinal circulation. Instead of reversing damage, erucamide significantly slowed retinal degeneration by preserving the remaining healthy tissue.
Discovery of TMEM19 Explains How Erucamide Works
The researchers also identified a previously poorly understood protein called TMEM19 as the binding partner for erucamide. TMEM19 was found mainly on retinal microglia, the immune cells responsible for monitoring retinal health.
When scientists reduced TMEM19 activity, erucamide could no longer activate the myeloid cells, and its protective benefits disappeared entirely. This demonstrated that the erucamide-TMEM19 pathway is essential for triggering the retina's natural repair response.
The study further showed that treated animals experienced significant improvements in retinal function, particularly in signals generated by inner retinal cells. Although damaged photoreceptors were only partially preserved, healthier communication between retinal cells appeared to improve overall visual signaling.
Why the Discovery Matters
The findings are particularly important because many retinal diseases share common features despite having different causes. Whether the disease results from aging, diabetes, or inherited genetic mutations, the breakdown of communication between neurons, blood vessels, glial cells, and immune cells is a major contributor to vision loss.
The researchers believe therapies targeting the erucamide-TMEM19 signaling pathway may work across multiple retinal diseases rather than focusing on only one condition. The discovery also provides a promising alternative to stem cell therapies, which have faced challenges including limited survival of transplanted cells, possible immune rejection, and concerns about long-term safety.
Because erucamide is already naturally produced in the body, scientists hope enhancing its activity may provide a safer way to reinforce the retina's existing protective mechanisms.
Future Research and Therapeutic Development
Despite the encouraging results, several challenges remain before erucamide can become a treatment for patients. Because the molecule does not dissolve well in water, researchers are continuing to improve drug delivery technologies and are designing modified versions of erucamide that may remain active for longer periods.
Future studies will also investigate whether similar naturally occurring fatty acid amides possess even stronger protective properties. Scientists believe these discoveries could eventually lead to a completely new class of small-molecule therapies capable of slowing retinal degeneration while preserving vision in millions of patients.
Conclusions
This research significantly advances scientists' understanding of how the retina naturally responds to injury. By identifying erucamide as a critical signaling molecule and revealing the essential role of the TMEM19 protein, the investigators have uncovered a biological pathway that coordinates immune cells, blood vessels, nerve cells, and supporting retinal tissues. Rather than replacing damaged cells, future treatments may strengthen the eye's own protective systems, potentially offering a broadly applicable strategy for slowing vision loss across several currently incurable retinal diseases.
The study findings were published in the peer reviewed journal: Nature Neuroscience.
https://www.nature.com/articles/s41593-026-02341-w
For the latest in ophthalmology, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/ophthalmology-(eye-diseases)
https://www.thailandmedical.news/articles/glaucoma-news
Share
Tweet
Share
